Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Maglio (Baronissi (SA), Italy), C. Vitale (Baronissi (SA), Italy), S. Pellegrino (Baronissi (SA), Italy), C. Calabrese (Naples, Italy), R. Parente (Baronissi (SA), Italy), M. Triggiani (Baronissi (SA), Italy), C. Stellato (Baronissi (SA), Italy), C. Pelaia (Catanzaro, Italy), G. Pelaia (Catanzaro, Italy), A. Vatrella (Baronissi (SA), Italy). Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy. 2265

Member's Comments

No comment yet.

Related content which might interest you: Immunoproteasome function as a potential biomarker for asthma severity and response to therapy Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease Year: 2021 Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Anti-IL5 therapy could prevent lung function decline in severe eosinophilic asthma: data from the belgian severe asthma registry Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021 Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score. Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Identifying patients with severe asthma that will be benefit from biological therapy Source: Virtual Congress 2020 – Rethinking asthma Year: 2020 Clinical characteristics, lung function, quality of life, exercise capacity and inflammatory biomarkers in induced sputum and serum in children and adolescents with uncontrolled severe asthma. Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019 Comparison of residual eosinophilic inflammation in the distal airway of patients with well-controlled asthma using different drug combinations of asthma treatment Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Assessment of maximal airway response before and after inhaled corticosteriod treatment in new diagnosed asthma patients Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 The role of biomarkers and effectiveness of maintenance therapy in stable severe COPD Source: International Congress 2017 – COPD management Year: 2017 The clinical importance of small airway involvement in patients with asthma and COPD Source: International Congress 2019 – PG12 Recent advances in small airways diseases in patients with asthma and COPD Year: 2019 Early treatment response may predict long-term mepolizumab benefit in severe asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Evaluation of the individual bronchodilator response in patients with severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 246s Year: 2002 Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations? Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019 Year: 2019 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - PG13 Asthma: pathology and treatment Year: 2009 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - MP7 - Targeting airway inflammation in asthma: current and future therapies Year: 2009 Fluctuations in airway function: chronic asthma seen as a complex dynamic system Source: Annual Congress 2006 - Physiological year in review Year: 2006 Eosinophils in bronchial biopsy predict functional response to biological therapy in severe asthma Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017